Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...
A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...
Swarms of satellites launched by SpaceX and other companies are disrupting astronomical observations. Here's how scientists ...
Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.
Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...
Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...
The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...
Home > Pressemitteilung: Major Progress in the Development of ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
RNAi – functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking as ...
Fintel on MSN6d
JP Morgan Upgrades Alnylam Pharmaceuticals (ALNY)Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...
2007). The availability of hundreds of genes expressed in planarian neurons, coupled with the ability to silence them through RNA interference, has facilitated the unraveling of the molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback